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Abstract
A considerable number of patients with a cancer diagnosis are of childbearing age and have not satisfied their desire for a family. Despite 
ovarian cancer (OC) usually occurring in older patients, 3%–14% are diagnosed at a fertile age with the overall 5-year survival rate being 
91.2% in women ≤44 years of age when it is found at 1A–B stage. In this scenario, testing the safety and the efficacy of fertility sparing 
strategies in OC patients is very important overall in terms of quality of life.
Unfortunately, the lack of randomised trials to validate conservative approaches does not guarantee the safety of fertility preservation strat-
egies. However, evidence-based data from descriptive series suggest that in selected cases, the preservation of the uterus and at least 
one part of the ovary does not lead to a high risk of relapse. This conservative surgery helps to maintain organ function, giving patients of 
childbearing age the possibility to preserve their fertility.
We hereby analysed the main evidence from the international literature on this topic in order to highlight the selected criteria for conserva-
tive management of OC patients, including healthy BRCA mutations carriers.
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Introduction
Gynaecological cancers are relatively frequent in the female population, with a global estimated incidence of 222,700 new cases in Europe 
[1]. Thus, a considerable number of patients affected by gynaecological tumours are of childbearing age at diagnosis and have not com-
pleted their desire for a family. Among all ovarian cancers (OCs), 12% are diagnosed in fertile women. The overall 5-year survival rate for 
all OCs in women ≤44 years of age is 91.2% when it is found at stages 1A and 1B [2]. Owing to increased survival, there is a new focus on 
the quality of life (QoL) for cancer patients. As evidenced by a Wenzel study in which women survived lymphoma, gestational trophoblastic 
tumour and cervical cancer, and who were unable to procreate after cancer treatment, but who still desired fertility, experienced significant 
regret, so proving that the desire for reproduction is an important factor contributing to improved QoL [3]. However, compared to other 
tumours, the gonadotoxicity derived from medical and/or radiation treatment did not represent the main cause of infertility. In particular, for 
women with OC, it can be especially difficult to maintain reproductive function because the ovary is the site of primary cancer. Thus, ovaries 
containing ovarian follicles become a target to be treated to remove cancer cells although they should be protected for fertility.
Psychological impact
As already demonstrated, cancer is a disease that not only causes damage and physical limitations but also causes psychological changes 
with negative impacts. Patients with cancer have a high rate of comorbid psychiatric disorders, as well as nonspecific psychological distress 
[4, 5]. Most patients with epithelial OC (EOC) experience some level of ongoing psychological distress throughout the course of their dis-
ease with particular evidence of depression and anxiety [6–8]. In a study conducted in 2006, Mc Corkle et al demonstrated that women with 
gynaecological cancer have a greater tendency towards depression, thanks to many changes in their marriages, work or financial statuses 
[9]. Besides, a radical reduction in QoL helps to increase an anxious and depressed state [10]. In fact, women suffering from OC experience 
as their first discomfort changes in their body due to radical surgery or the administration of cytotoxic therapies. Poor body image has been 
significantly associated with fatigue and poor sexual functioning, particularly among women who were premenopausal at diagnosis. Sexual 
problems may be secondary to the effects of surgery, chemotherapy or menopause, or may be due to a partner’s sexual issues or relation-
ship problems. Women may complain of dyspareunia, loss of desire or other sexual dysfunction [11]. It’s important to identify patients with 
particular risk of developing sexual and psychological problems using the available questionnaire about sexual function before cancer, cur-
rent sexual activity and how cancer is modifying sexual health and relationship with the partner: Brief Index of Sexual Functioning for Women 
or the Female Sexual Function Index [12, 13].
Fertility-sparing methods
There are several techniques for the preservation of fertility in case of the necessity of radical surgery:
Embryo cryopreservation
Since 1983 with the first case, embryo cryopreservation is a proven method of fertility preservation. In women with OC, this procedure 
can be performed only if there is no therapeutic urgency as at least 2–3 weeks is usually necessary to carry out the procedures. it is not 
recommended to stimulate the ovaries, after the beginning of chemotherapy, because of the proven poor ovarian response. Actually, the 
ovulation induction protocols from the third day of the cycle, or the one with the administration of subcutaneously injected gonadotropins 
for 8–14 days are effective. For this procedure, a male partner or a male gamete donor is required [14].
Oocyte cryopreservation
Oocyte cryopreservation could be a valid option for patients with unilateral OC. Oocytes could be acquired during unilateral ovariectomy. 
Controlled ovarian hyperstimulation (COH) is not indicated in case of early intervention nor in prepubescent patients, and it is also not indi-
cated in patients with granulosa cancer due to rapid hormone-dependent proliferation. The oocytes can be acquired immature or mature. 
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Immature oocytes are acquired without the need of stimulation and subsequently are matured in vitro either before freezing or after thawing 
[15]. In addition, immature oocytes are more resistant to cryoinjury than mature oocytes since they do not contain a metaphase spindle. 
Rienzi et al showed that to achieve successful live birth through cryopreserving oocytes, at least eight oocytes are required for patients 
aged <38 and more than eight oocytes in patients aged >38 [16]. Compared to embryo cryopreservation, oocyte freezing is still associated 
with lower pregnancy rates (4.6%–12% versus 30%–40%). In this case, no partner is needed [17].
Ovarian cryopreservation
Ovarian cryopreservation followed by heterotopic implantation or orthotopic implantation is a technique that can be offered to patients who 
require early treatment and those who have hormone-sensitive tumours, in fact, no ovarian stimulation is required. It is also the only solution 
to offer to prepubertal patients. Ovarian tissue preservation is not an option for women with OC or at high risk of developing OC (BRCA1-2 
carriers patients). However, it has been hypothesised that if the ovarian tissue is frozen when the woman is very young and at very low risk 
of OC, cryopreservation of ovarian tissue may still be considered [18].
However, it must be considered that surgery is not the only procedure that damages fertility in women with OC. There is also a harmful 
effect of chemotherapy and radiation therapy.
The most effective chemotherapeutic regimen for epithelial OC is a combination of a platinum compound and a taxane. Alkylating agents 
are gonadotoxic chemotherapeutic agents and have most consistently been associated with ovarian failure in a dose-dependent manner. 
The American Society of Clinical Oncology Clinical Practice Guideline Committee stated that women treated with high doses (≥ 5 g/m2) of 
alkylating agents have a high risk (more than 70%) to develop permanent amenorrhoea [19]. Alkylating agents determine oocytes dam-
age via single-stranded DNA breaks and targets cells at every stage of cell cycle, preferentially on primordial follicles [20]. The impact on 
fertility of taxanes and platinums is an intermediate risk level (30%–70%) of amenorrhoea, whereas protocols containing antimetabolites 
and anthracyclines are related to a lower risk (less than 30%) [20]. Radiation is reserved for chemotherapy-resistant OCs. Lower doses 
of radiation therapy are used for OCs, resulting in germ cell death in the contralateral ovary in the case of unilateral oophorectomy. Germ 
cells are the most sensitive cells in the body to radiation and chemotherapy [21]. The reason for this high sensitivity is assumed to be 
related to the presence of a TAp63 molecule, a main molecule of the apoptotic pathway. TAp63, as a guardian of germ cells, decides the 
fate of cells depending on the intensity of DNA damage [22]. It is thought that this is a unique phenomenon in female germ cells that protect 
the genetic material transmission from generation to generation. c-Abl, an upstream molecule, has been shown to regulate TAp63 [23]. 
Through understanding the precise pathway of germ cell death and targeting the pathway, germ cells can be protected from the off-target 
effects of radiation and chemotherapy. Developing fertiprotective agents has long been studied to protect oocytes against radiation and 
chemotherapy. Gonadotropin-releasing hormone (GnRH) antagonists and agonists are used for this function. The role of temporary ovarian 
suppression with GnRHa during chemotherapy has been accurately studied for the past years with contrasting results [24–27]. However, 
recent data show the impact of this strategy in breast cancer patients [28, 29] with a significant reduction in the risk of treatment-induced 
premature ovarian failure and higher pregnancy rates in patients receiving GnRHa during chemotherapy [30–32].
It is clear that the choice to perform fertility sparing surgery must take into account the type of tumour and the stage.
For this reason, we reported the current available data about fertility preservation strategies in ovarian tumours, according to histotype as 
follows:
Borderline tumours
Borderline ovarian tumours (BOTs) comprise 10%–20% of ovarian epithelial tumours and are typically diagnosed during reproductive 
years. Survival rates are about 99%, with a 70-month disease-free survival in cases of stage I tumours, and the survival rate in cases of 
stage III tumours is about 89% [33, 34]. While some authors recommend bilateral salpingo-oophorectomy as the initial treatment for early-
stage BOT, others have also reported excellent results with more conservative treatments, including cystectomy or unilateral salpingo-
oophorectomy [35]. Fertility sparing surgery was associated with a higher risk of relapse but not with increased mortality [20]. Factors 
associated with a higher risk of relapse after conservative surgery for early-stage BOT include age <30, bilaterality and type of surgery 
(cystectomy versus adnexectomy). Micropapillary histologic pattern, stage and presence of invasive implants are other well-recognised 
Re
vi
ew
 4 www.ecancer.org
ecancer 2018, 12:885
risk factors [36, 37]. Women desirous of offspring should be made to have regular intercourse after 3 months from surgery, in those women 
who have no partner or because they want to postpone pregnancy oocyte cryopreservation after ovarian stimulation is advised. The data 
in the literature suggest that it is unclear whether assisted reproductive techniques are associated with an increased risk of recurrence, but 
it is underlined that most recurrences (11/12) were BOT and were successfully managed by surgery [38].
Some other methods could be used in the future. Currently, we are waiting for the publication of data about two patients that underwent 
ovarian corticectomy as a novel technique in fertility sparing [39].
Studies concerning BOT and fertility preservation are summarised in Table 1 with the respective conception rates.
Germ cell tumours
Malignant ovarian germ cell tumours (MOGCTs) are rare cancers (3%–5% of ovarian tumours) but they are the ones that most affect 
younger women—83% of cases occur in women under the age of 40 years, often in women in their teens and twenties. For this reason, the 
preservation of fertility is an important aspect in the management of these neoplasms [40]. Thanks to the rapid growth and early symptoms 
secondary to capsular distension, necrosis and haemorrhage, the tumour is frequently diagnosed in stage I unlike to epithelial OC [40]. 
Unilateral salpingo-oophorectomy with peritoneal staging and retroperitoneal staging if indicated, is the treatment of choice in early stage 
MOGCT with vertical midline incision, careful abdominal exploration with inspection and palpation of all peritoneal surfaces, multiple biop-
sies of peritoneum, omentectomy, with no survival difference after unilateral or bilateral salpingo-oophorectomy when MOGCT are confined 
to one ovary [41]. Bilateral disease is uncommon and no biopsy is advised owing to the risk of extra adhesions and impairment of ovarian 
reserve unless there are macroscopically suspicious areas in the contralateral ovary [42].
• Pure dysgerminoma: several authors suggest fertility-sparing treatment for all stages with a disease-free survival in 10 years of >90% 
and overall survival 100% [43].
• Yolk sac tumours (non-dysgerminomatous tumours): for early stage, fertility-sparing surgery is feasible, in case of a higher stage, 
standard-dose bleomycin, etoposide and cisplatin (BEP) chemotherapy following fertility-sparing surgery has been associated with 
favourable overall survival rates and no apparent compromise of fertility rates [44]. Serum alpha-feto-protein (AFP) is a reliable 
marker for diagnosis and may be used in clinical decision-making after surgery or for advanced disease management [45]. Even 
though three courses of BEP are the standard adjuvant therapy after conservative surgery for early-stage YST, some patients can 
also be carefully followed up without treatment if AFP after surgery declines consistently.
• Immature ovarian teratoma (non-dysgerminomatous tumours) stage 1 grade 2–3 adjuvant chemotherapy following fertility-sparing 
surgery has been recommended by some authors, but several studies suggest an expectant approach with BEP only in case of 
relapse [46]. Reproductive function, on the other hand, has been reported to be relatively good, with more than 80% of patients retain-
ing reproductive function after chemotherapy and surgery [42]. Oocyte cryopreservation could be proposed to all adolescent patients 
and to all those who have not yet planned a pregnancy and a COH could also be considered after 12 months from CT.
Malignant sex cord-stromal tumours
Malignant sex cord-stromal tumours are rare and include granulosa cell tumours (most common) and Sertoli-Leydig cell tumours; they are 
typically associated with a good prognosis. Most of the patients with granulosa tumours present with early-stage disease. The disease is 
typically indolent. Patients with stage IA or IC sex cord-stromal tumours desiring to preserve their fertility should be treated with fertility-
sparing surgery. Although complete staging is recommended for all patients, lymphadenectomy may be omitted for stage IA or IC. For 
patients who choose fertility-sparing surgery, completion surgery should be considered after childbearing is finished. For patients with high-
risk stage I tumours (tumour rupture, stage 1C, poorly differentiated tumour and tumour size >10–15 cm), observation or consideration of 
platinum-based chemotherapy should be indicated. Patients with surgical findings of low-risk stage I tumour (i.e. without high-risk features) 
should be observed. Inhibin levels can be followed if they were initially elevated [47].
Table 2 summarises studies about granulosa cell tumours and fertility preservation.
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Table 1. BOTs and fertility.
Study Patients Stage Pregnancies Patients who conceived Patients who attempted  to conceive Conception rate (%)
Morris et al 2000 43 IA–II 25 12 24 27.91
Zanetta et al 2001 189 IA–III 41 44 NR 23.28
Morice et al 2001 44 IA–III 17 14 NR 31.82
Cameatte et al 2002 17 II–III 8 7 9 41.18
Fauvet et al 2005 162 IA–III 30 21 65 12.96
Park et al 2009 184 IA–III 33 27 31 14.67
Uzan et al 2009 41 II–III 18 14 NR 34.15
NR = not reported
Table 2. Granulosa cell tumours and fertility.
Study Patients Stage Pregnancies Patients who conceived Patients who attempted  to conceive Conception rate (%)
Low et al 2000 74 IA–IV 16 19 20 25.68
Zanetta et al 2001 138 IA–IC 55 28 32 20.29
Tangir et al 2003 64 IA–IV 47 29 38 45.31
Zanagnolo et al 2004 39 IA–IC 11 36 NR 92.31
Nishio et al 2006 30 IA–IV 4 8 12 26.67
Chan et al 2008 313 IA–IV NR 29 38 9.27
NR = not reported
Epithelial tumours
The standard treatment for patients in International Federation of Gynecology and Obstetrics (FIGO) stage I–II EOC is based on total 
hysterectomy, bilateral salpingo-oophorectomy, peritoneal sampling, omentectomy, both pelvic and para-aortic lymphadenectomy [48]. 
According to the available guidelines, in women wishing to maintain fertility, conservative surgery can be performed, for all grades at 
stage IA or IC [49, 50]. While this approach is still debated for high-risk patients (clear cell, stage> or equal IAG3) [50, 51]. In the recent 
ESMO and ESGO guidelines, a conservative approach is limited to G1-2 IA and IC EOC with unilateral involvement, in the case of 
mucinous, serous, endometrioid or mixed histotype [50, 52]. In the largest retrospective series available including 1,189 patients with 
early EOC, 432 of whom treated conservatively, stage IC and grade 3 were the only independent predictors of survival [53]. Fruscio 
et al, in a retrospective study, unlike Wright JD, in a 240 patients with malignant early stage/EOC treated with fertility-sparing surgery, 
confirmed that grade of nuclear differentiation G3 was the only predictor for survival, associated with a significant higher rate of distant 
recurrence (RFS: Hazard ratio [HR]: 4.2, 95% confidence interval [CI]: 1.5–11.7, P = 0.0067; OS: HR: 7.6, 95% CI: 2.0–29.3, P = 0.0032) 
[51]. However, patients with G3 tumours, analysed in this study, have a comparable prognosis in terms of disease-free and overall sur-
vival compared to patients with G3 neoplasia included in the ICON1/ACTION trial where all women underwent radical surgery [54, 55]. 
Some studies have indeed shown that in the case of macroscopically undamaged contralateral ovaries, the risk of microscopic involve-
ment was 0%–2.5% [48, 56]. In the case of endometrial histotype, an endometrial biopsy is suggested, while in the case of mucinous 
histotype, appendectomy is recommended to exclude intestinal origin of tumour. Regarding the surgical procedure, the laparoscopic 
approach has been described as a feasible technique by several authors [48, 57]. However, tumours greater than 10 cm are probably 
correlated with a higher risk of rupture and spillage that may occur in 88% versus 9% through laparoscopy compared to laparotomy [58]. 
In a Bentivegna analysis, it has been observed that most relapses occurring after a conservative surgical approach are extra ovarian, 
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suggesting that the preservation of one ovary is not necessarily the cause of the recurrence [59]. Moreover, the adjuvant therapy in 
early-stage EOC improves survival and delays recurrence in patients with IC stage, as demonstrated by a multicentre open randomised 
trial, with 477 patients, in fact, the group who receive adjuvant chemotherapy immediately following surgery had better overall survival 
(HR of 0.66, 95% CI = 0.45–0.97; P = 0.03) and a recurrence-free survival (HR = 0.65; 95% CI = 0.46–0.91; P = 0.01) [60].
Studies concerning EOCs and fertility are collected in Table 3.
Otherwise, for healthy BRCA mutated patients with elevated risk for OC, other therapeutic options are adopted.
Currently, mutation carriers should complete childbearing and then undergo a salpingo-oophorectomy around 35–40 years if BRCA1-
mutated and 45–50 years if BRCA2 mutated, while concurrent hysterectomy is not recommended [61–64]. Thus, for this group of patients, 
fertility could be impacted by two different agents: treatments of eventual cancer and prevention strategies. It has been hypothesised 
that carrying BRCA mutations, especially BRCA1, can be associated with decreased ovarian reserve, increased fertility-related problems 
and primary ovarian insufficiency that can lead to infertility and early menopause [65]. Despite the strong rationale and preclinical results 
suggesting this hypothesis, conflicting clinical data are available and they do not show a significant difference among BRCA carriers and 
non-carriers. Hence, a negative impact of carrying a BRCA mutation, mainly BRCA1 but also BRCA2 [66, 67], on women’s reproductive 
performance must be kept in consideration. For the lack of reproduction studies about BRCA-mutated breast cancer patients, the safety 
and efficacy of the different strategies for fertility preservation and the feasibility of having a pregnancy after diagnosis should be considered 
a research priority [68]. Approaching this group of patients, some authors suggest performing anti-Müllerian hormone measurement and 
antral follicle count in order to evaluate the ovarian reserve. Therefore, young adults with BRCA mutation should be counselled regarding 
this potential decrease of ovarian reserve [69].
In cases needing fertility preservation, oocyte cryopreservation could be an option for BRCA-mutated women who undergo surgery not 
at 40 years old but earlier, when the ovarian reserve and its quality are better [70]. In contrast, ovarian tissue cryopreservation is not rec-
ommended, for the increased risk of malignant transformation [71, 72]. However, two live births have been reported in the literature, with 
uneventful pregnancies, in BRCA-mutated breast cancer patients that underwent ovarian tissue cryopreservation. The former was 16 
months after transplantation, with a previous miscarriage—the latter happened with the recovery of ovarian function 5 months after trans-
plantation, followed by a spontaneous pregnancy 3 months later [73, 74].
Salpingectomy with delayed oophorectomy, preserving natural follicular cycle, is another option for prophylactic treatment. However, this 
surgery strategy is still not recommended as the primary approach [62, 63].
Table 3. Epithelial OCs and fertility.
Study Patients Stage Pregnancies Patients who conceived Patients who attempted  to conceive Conception rate (%)
Zanetta et al 1997 56 IA–II 17 20 NR 35.71
Morice et al 2001 25 IA–II 3 4 4 16.00
Schilder et al 2002 52 IA–IC 26 17 24 32.69
Morice et al 2005 34 IA–IC 10 9 NR 26.47
Anchezar et al 2009 18 IA–IIIB 7 6 7 33.33
Schlaerth et al 2009 20 IA, IC 9 6 NR 30.00
Park et al 2008 62 IA–IIIC 22 15 19 24.19
Raspagliesi et al 1997 10 IA–IC 2 3 5 30.00
Borgfeldt et al 2007 23 IA, IC 30 15 NR 65.22
NR = not reported
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Carcinosarcomas
Carcinosarcomas Malignant Mixed Müllerian Tumours (MMMTs) are rare tumours with a poor prognosis. Patients with MMMTs are not 
candidates for fertility-sparing surgery regardless of age.
Future perspectives 
In vitro ovarian follicle growth
The greater risk associated with cryopreserved ovarian tissue autotransplantation is the possibility of a tumour re-implantation and dissemi-
nation, also in the contralateral ovary transplantation that could also contain tumour cells [71]. The possibility of using in vitro follicles could 
represent a chance to preserve fertility in young patients with OC; in fact, recently, mature human follicles have been successfully cultured 
in vitro to produce metaphase II stage oocytes which could be used for IVF [75, 85]. This technique does not require hormonal stimulation 
and can also be offered in prepubertal patients.
In vitro ovarian follicle maturation
A future possibility to offer to young cancer patients could be follicular maturation in vitro. In fact, a portion of cortical ovarian cysts from 
patients with cancer could be treated with phosphatase and tensin homolog inhibitor or AKT activator, determining in vitro ovarian follicle 
maturation.
These follicles can be kept for future use [76].
Protection against germ cell damage using fertoprotective agents
Fertility sparing surgical approaches in patients with early-stage OC, described above, have some limitations, including cost, time, acces-
sibility to dedicated centres and gonadotoxicity related to procedures. Therefore, the need arises to obtain adjuvants that can inhibit or 
reduce the side effects of various anticancer drugs with the aim of protecting the pool of dormant follicles.
Some molecules have already been extensively studied for this role, for example, sphingosine-1-phosphate (S1P), imatinib mesylate, 
amifostin, tamoxifen and GnRH antagonists and agonists. There are emerging studies on the fertoprotective role of melatonin. In fact, 
melatonin reduces the adverse effects of chemotherapy by removing superoxide anion, hydrogen peroxide and peroxyl radical.
However, it is necessary to test agents and to develop new and efficient fetoprotective agents in the preservation of the ovarian reserve 
for OC patients [77].
Actual and future perspectives for hysterectomised women (beyond uterus transplantation)
Women who must undergo hysterectomy will need to consider other options, such as surrogacy, even if they have cryopreserved oocytes. 
Recently, successful uterine transplantation was reported but the application of this technique in clinical practice is still limited [78]. Despite 
the interesting results reported by Brännström M et al about the use of uterus transplantation in either benign and malignant conditions, the 
use of high doses of immunosuppressive agents, the risk of cancer recurrence in immunocompromised patients and the possible vascular 
abnormalities after pelvic radiation must be considered before taking this approach in consideration to cancer patients. However, it could 
represent a revolutionary approach for the management of gynaecologic cancer patients with fertility preservation purposes [78].
Studies about uterus transplantation and its outcomes are summarised in Table 4.
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Table 4. Uterus transplantation and outcomes.
Pts Age Cause of uterus absence Type of transplantation Results
Fageeh W et al 2002 1 26 Post-partum haemorrhage Allotransplantation from 
alive donor
Histerectomy for acute vascular thrombosis
Ozkan et al 2013 1 21 Complete müllerian 
agenesis
Allotransplantation from a 
deceased donor
Pregnancy with early miscarriage
Brännström et al 2014
Johannesson et al 2015
9 31.5 – Eight MRKH
– One cervical cancer
Allotransplantation from 
alive donor
–  Seven uteri remain viable (with mild rejection 
in four patients reversed with corticosteroids) 
–  Two severe rejections caused by bilateral 
thrombotic arterial occlusions
Brännström et al 2014 1 35 MRKH Allotransplantation from 
alive donor
One live birth
MRKH = Mayer Rokitanscky Küster Hauser syndrome
Conclusions
The mean 5-year survival rate for OC is 47.4% but the cancer stage at diagnosis has a strong influence on the length of survival [79]. 
Most women with Stage I OC have an excellent prognosis. Stage I patients with grade I tumours have a 5-year survival of over 90%, as 
do patients in stages IA and IB. These percentages significantly decrease for the other stages: Stage II OC has a 5-year survival rate of 
approximately 70%, Stage III about 39% and Stage IV only 17% [79]. Other factors impact a woman’s prognosis, including her general 
health, the grade of cancer and the histotype. Among women with distant disease, a higher risk of mortality was observed within the 
first 2 years after diagnosis for mucinous, clear cell and carcinosarcoma compared with high-grade serous, with the most striking haz-
ard ratio observed in the first year after diagnosis for mucinous (HR 1⁄4 3.87, 95% CI 1⁄4 3.45–4.34) [80]. Cumulatively, both localised/
regional and distant-stage low-grade serous and endometrioid carcinomas had the most favourable outcomes [81]. So, it is clear that dif-
ferent cancers need different approaches. Moreover, it is important to distinguish non-epithelial ovarian neoplasms because guidelines 
allow gynaecologists to perform more conservative surgery [82–84]. Therefore, since there is no scientific evidence to support a better 
prognosis with demolitive surgery, conservative surgery can be proposed in the initial stages with adequate counselling. Obviously, the 
choice must be strictly based on an accurate staging of the disease, surgically reached, and on the evaluation of prognostic factors as 
grading and histotype.
In the case of negative prognostic factors, chemotherapy can have a fundamental role in allowing a fertility sparing approach.
To sum up, it is essential to identify tumours at an initial diagnosis that allows the ovarian and uterus tissue to be maintained because only 
initial stages can be treated with conservative procedures reducing danger for the patients. Different approaches for each type of tumour 
are summarised in Figure 1.
Unfortunately, we know that there is no OC screening test but an annual pelvic ultrasound should be proposed to all women. For their 
predisposition to develop OC, BRCA-mutated patients are encouraged to perform closer checks and monitoring of the marker, before the 
oophorectomy, the most effective measure for reducing this risk.
It is true that there will be the possibility of new techniques for patients radically treated (such as uterus transplantation), but this is still very 
far from common clinical practice.
As long as these methods do not become habitual, early diagnosis, and thus fertility sparing surgery, is the only chance for these women 
to become pregnant.
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Figure 1. Fertility sparing strategies in OC patients. RR = recurrence rate, FSF = fertility sparing surgery, RS = radical surgery.
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